Mizuho Securities USA LLC Boosts Position in Insulet Co. (NASDAQ:PODD)

Mizuho Securities USA LLC grew its stake in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 5,928.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 325,821 shares of the medical instruments supplier's stock after buying an additional 320,416 shares during the quarter. Mizuho Securities USA LLC owned 0.46% of Insulet worth $75,835,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in Insulet by 2.1% during the 1st quarter. Vanguard Group Inc. now owns 8,199,114 shares of the medical instruments supplier's stock valued at $1,405,328,000 after buying an additional 169,506 shares during the period. Baillie Gifford & Co. grew its stake in shares of Insulet by 20.7% in the third quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier's stock worth $529,669,000 after purchasing an additional 389,639 shares during the last quarter. Clearbridge Investments LLC grew its stake in shares of Insulet by 6.0% in the second quarter. Clearbridge Investments LLC now owns 1,339,763 shares of the medical instruments supplier's stock worth $270,364,000 after purchasing an additional 75,526 shares during the last quarter. American Century Companies Inc. increased its holdings in Insulet by 18.7% during the 2nd quarter. American Century Companies Inc. now owns 885,669 shares of the medical instruments supplier's stock valued at $178,728,000 after purchasing an additional 139,246 shares during the period. Finally, Marshall Wace LLP bought a new position in Insulet during the 2nd quarter valued at approximately $99,978,000.

Insulet Stock Down 0.4 %

Shares of NASDAQ:PODD traded down $1.04 on Friday, hitting $260.12. 916,752 shares of the company traded hands, compared to its average volume of 780,524. The company has a market cap of $18.25 billion, a PE ratio of 44.54, a PEG ratio of 4.11 and a beta of 1.22. The stock has a 50 day simple moving average of $237.77 and a 200-day simple moving average of $207.47. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $279.40. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21.

Analysts Set New Price Targets

PODD has been the subject of a number of recent analyst reports. UBS Group upped their target price on Insulet from $211.00 to $223.00 and gave the company a "neutral" rating in a report on Friday, August 9th. Raymond James upped their price objective on shares of Insulet from $213.00 to $260.00 and gave the stock an "outperform" rating in a report on Monday, October 14th. Morgan Stanley lifted their target price on shares of Insulet from $234.00 to $317.00 and gave the company an "overweight" rating in a research note on Monday, November 11th. BTIG Research boosted their price target on shares of Insulet from $260.00 to $270.00 and gave the company a "buy" rating in a research report on Friday, November 8th. Finally, Sanford C. Bernstein initiated coverage on shares of Insulet in a report on Wednesday, November 6th. They issued an "outperform" rating and a $300.00 price objective for the company. Three investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. According to data from MarketBeat, Insulet currently has an average rating of "Moderate Buy" and an average price target of $253.27.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.